Home
FDA Calendar
About & More
Testimonials
Useful Links
Our Disclaimer
Updates and Roadmap
Contribute
Create Company Profile
Create Drug Profile
Browse
Contact
FDA Calendar for Biomoda, Inc. (BMOD)
Login Now
|
Register (free)
Biomoda, Inc. is a development-stage company. The Company is an invitro diagnostics company that develops assays, or tests, to detect cancer. These assays are performed in clinical reference laboratories using body-fluid samples. This technology is based on a licensed patent from Los Alamos National Laboratories. The technology is based on a molecule that has an affinity to bind with cancer cells and it fluoresces red under ultra violet light. It is a porphyrin molecule. This technology works with a range of cell types. The Company is in the process of developing a line of assays for a variety of cancers based on adaptations of this technology. Biomoda's first product is an assay for lung cancer.
Around The Net
Latest News
Twitter Stream
Yahoo Message Board
Google Message Board
You are reading news provided by a variety of web sources.
Biomoda, Inc. Receives Patent In Japan
7 month(s)
Biomoda, Inc. Announces Top-line Results Of Pilot Study For Lung Cancer
10 month(s)
Biomoda, Inc. Names New Chief Executive Officer
1 year(s)
Biomoda, Inc. Announces Patent In Canada
1 year(s)
Biomoda, Inc. Announces New Patent In Mexico
1 year(s)
Drug Pipeline
Drug Name
Type Of Drug
FDA Status
Drug Phase
This company currently does not have any drugs. If you would like to create one please
click here
.
Events
No future events listed at this time, please check back later.
Outcome
Past Events
Add New Event
In order to write a comment you must first login.
Login
or
Register
(for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login
or
Register
(for free!)
Add Link
$0.00
0
1/1/0001 12:00:00 AM
Sponsors
Other Links
Corporate Website
Analyst Estimates (MarketWatch)
CNN Money
Google Finance
Guru Focus
Major Holders
MSN Money
SEC Filings (EDGAR Online)
Seeking Alpha
Yahoo! Finance